Matrix metalloproteinase Mmp-1a is not required for growth and fertility in mice and has a role in lung cancer progression by modulating inflammatory responses

Overexpression of MMP-1 is associated with non-small cell lung cancer

Over expression of MMP-1 is associated with lymphatic metastasis of nonsmall cell lung carcinoma

matrix metalloproteinase 1, 3 and 12 haplotypes may associated with development of lung cancer, particularly among never smokers and men

The -1607(1G>2G) in promoter region of MMP1 is associated with susceptibility to lung cancer in Northwestern Chinese population of Han nationality.

epiregulin, COX2, and MMP1 and 2 collectively facilitate the assembly of new tumour blood vessels, the release of tumour cells into the circulation, and the breaching of lung capillaries by circulating tumour cells to seed pulmonary metastasis

MMP1 is associated with an increased risk for lung cancer, modified by smoking.

SNPs in MMP1, MMP2, MMP7 and MMP12 have roles in response to chemotherapy in lung cancer

high plasma are associated with advanced-stage of the disease and lower survival rate of lung cancer patients

The current study demonstrated that the MMP-1 -1607 1G-to-2G polymorphism is associated with susceptibility to both development and progression of lung cancer.

MMP1-1607 1G/2G polymorphism is associated with lung cancer.

MMP1-1607 1G/2G polymorphism increased lung cancer risk in Asians.

Pit-1 regulates MMP-1 and MMP-13, and that inhibition of MMP-13 blocked invasiveness to lung in Pit-1-overexpressed breast cancer cells.

Serum MMP-1 level showed a possibility as a prognostic biomarker in non-small cell lung cancer.

rs1144393 in the MMP1 promoter region can be a predictor of grade >/= 2 RILI in lung cancer patients treated with thoracic radiation.

Data show that matrix metalloproteinase 1 (MMP-1) as a critical downstream target of golgi associated kinase 1B (FAM198B) and implicate FAM198B as a potential tumor suppressor and to be a prognostic marker in lung adenocarcinoma.

This is the first study to indicate that the genotypes of MMP1 promoter -1607, do not significantly confer susceptibility to lung cancer in a Taiwanese population.

this study provides insights into the development of a possible alternative therapy manipulating MMP-1 and the mTOR signaling pathway in Epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma.

MMP1-1607 1G>2G polymorphism is a risk factor for developing lung cancer(Meta-Analysis)

Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.